June 10, 2008 - Sanofi-aventis announced the results of ARPEGGIO, the first trial of rimonabant in patients with type 2 Diabetes, not adequately controlled with insulin therapy. These results were presented today at the 68th Scientific Sessions of the American Diabetes Association, in San Francisco.Rimonabant 20 mg significantly improved HbA1c (a standard blood measure value that is indicative of a patients’ glucose for about two months) by 0.89% from the baseline value, and 0.64% over the control group. Glucose control was three times more pronounced when rimonabant was added than insulin and lifestyle advice alone.
The 368 type 2 diabetes patients participating to this 11-month trial had been treated with insulin for an average duration of six years prior to entering the study... [PDF] Sanofi-aventis' Press Release -
